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Adverse effects of elevated blood and bone lead
levels on cognitive function have been exam-
ined in various populations including children
(Banks et al. 1997; Canfield et al. 2003;
Needleman and Gatsonis 1990; Schwartz
1994), occupationally exposed adults (Balbus-
Kornfeld et al. 1995; Bleecker et al. 1997;
Fiedler et al. 2003; Schwartz and Stewart
2000; Stewart et al. 1999), and nonoccupa-
tionally exposed adults (Muldoon et al. 1996;
Payton et al. 1998; Weisskopf et al. 2004b;
Wright et al. 2003). These effects have been
assessed using primarily behavioral and neu-
ropsychologic evaluations and are some of the
most consistently reported impairments associ-
ated with lead exposure. Regarding the molec-
ular and cellular effects of lead exposure that
may underlie the behavioral effects, there is a
good deal of data from experimental studies in
animals, but relatively little is known about the
structural and functional correlates of lead-
related brain dysfunction in humans. A better
understanding of the underlying pathology
would not only have potential beneﬁts for pre-
vention and treatment of the adverse effects
but could also help identify those effects specif-
ically attributable to lead.
Magnetic resonance spectroscopy (MRS)
provides a noninvasive method with which to
monitor biochemical aspects of acute and
chronic stages of neurologic disease in the
human brain (Ross et al. 2006). The develop-
ment of spatially localized spectroscopic
methods that sample the relative levels of
metabolites from volumes of tissue defined
from magnetic resonance imaging (MRI)
scans has provided a basis for integrating the
biochemical information obtained by MRS
with the anatomical and pathological infor-
mation obtained from MRI. MRS has been
used as a method for assessing both neuronal
viability and demyelination. The use of MRS
in neurologic disease has grown rapidly over
the past decade, but the use of MRS in the
setting of environmental insult to the brain is
quite new. Earlier MRS studies of lead-
exposed individuals do suggest effects on
brain metabolites, but these studies focused
on small numbers of very highly exposed chil-
dren (Meng et al. 2005; Trope et al. 1998,
2001). Examination of the effects of exposure
levels to which a much larger population
would be exposed have not been done. We
assessed the association between cumulative
exposure to lead—as measured with K-X-ray
fluorescence (KXRF) of bone lead—and
brain metabolite ratios measured with MRS
among participants in the Department of
Veterans Affairs’ (VA) Normative Aging
Study (NAS), a community-based cohort of
elderly U.S. men with lead exposure similar
to a similarly aged cross-section of the general
U.S. population. 
Methods
Study population. This research was conducted
on a subgroup of the VA NAS, a multi-
disciplinary longitudinal study of aging in men
established by the VA in 1963 (Bell et al.
1966). The research herein was approved by
the Human Subjects Committees of the
Boston VA Medical Center, the Brigham and
Women’s Hospital, and the Harvard School of
Public Health. This cohort has been described
in detail elsewhere (Hu et al. 1996). Briefly,
healthy men from the general population in the
greater Boston, Massachusetts, area were
recruited in the 1960s. These men reported for
medical examinations every 3–5 years, at which
time they underwent clinical examinations and
completed extensive health and lifestyle related
questionnaires. The attrition rate for all causes
has been < 1% annually and the response rate
to mailed questionnaires that supplement
onsite examinations has been > 80%. 
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BACKGROUND: Exposure to lead is known to have adverse effects on cognition in several different
populations. Little is known about the underlying structural and functional correlates of such expo-
sure in humans. 
OBJECTIVES: We assessed the association between cumulative exposure to lead and levels of differ-
ent brain metabolite ratios in vivo using magnetic resonance spectroscopy (MRS).
METHODS: We performed MRS on 15 men selected from the lowest quintile of patella bone lead
within the Department of Veterans Affairs’ Normative Aging Study (NAS) and 16 from the highest
to assess in the hippocampal levels of the metabolites N-acetylaspartate, myoinositol, and choline,
each expressed as a ratio with creatine. Bone lead concentrations—indicators of cumulative lead
exposure—were previously measured using K-X-ray ﬂuorescence spectroscopy. MRS was performed
on the men from 2002 to 2004. 
RESULTS: A 20-µg/g bone and 15-µg/g bone higher patella and tibia bone lead concentration—the
respective interquartile ranges within the whole NAS—were associated with a 0.04 [95% confi-
dence interval (CI), 0.00–0.08; p = 0.04] and 0.04 (95% CI, 0.00–0.08; p = 0.07) higher myoinosi-
tol-to-creatine ratio in the hippocampus. After accounting for patella bone lead declines over time,
analyses adjusted for age showed that the effect of a 20-µg/g bone higher patella bone lead level
doubled (0.09; 95% CI, 0.01–0.17; p = 0.03).
CONCLUSIONS: Cumulative lead exposure is associated with an increase in the myinositol-to-crea-
tine ratio. These data suggest that, as assessed with MRS, glial effects may be more sensitive than
neuronal effects as an indicator of cumulative exposure to lead in adults. 
KEY WORDS: bone lead, choline, glia, hippocampus, myoinositol, N-acetylaspartate, neuronal viabil-
ity, proton MRS. Environ Health Perspect 115:519–523 (2007). doi:10.1289/ehp.9645 available
via http://dx.doi.org/ [Online 3 January 2007]Beginning in 1991 those who gave their
informed consent presented to the Ambulatory
Clinical Research Center of the Brigham and
Women’s Hospital for a KXRF measurement
of lead content in the tibia and patella bones.
We selected 105 men from the lowest quintile
of patella bone lead and 119 from the highest
quintile to participate in the MRS study. Of
these, 13 from the lowest and 12 from the
highest quintiles were either too sick or ineligi-
ble for MRS because of possible metal in their
body or we were unable to contact them (n =
27 from the lowest and 41 from the highest
quintile). Of the remaining 65 men from the
lowest and 66 from the highest quintile, 15
(23.1%) and 16 (24.2%), respectively, agreed
to undergo an MRS scan. These scans were
performed from 2002 through 2004. Bone
lead for these 31 participants was measured
between 1994 and 1999. 
Bone lead levels measured by KXRF. Bone
lead was measured at two anatomical sites—
the midtibial shaft and the patella—with an
ABIOMED KXRF instrument (ABIOMED,
Danvers, MA) as described previously (Hu
et al. 1998). The tibia and patella have been
targeted for bone lead research because these
two bones are primarily cortical and trabecular
bone, respectively, with different ramiﬁcations
in terms of toxicity (Hu et al. 1998). A 30-min
measurement was taken at the midshaft of the
left tibia and at the left patella, after each
region had been washed with a 50% solution
of isopropyl alcohol. The tibial midshaft was
taken as the midpoint between the tibial
plateau and the medial malleolus. The KXRF
beam collimator was sited perpendicular to the
ﬂat bony surface of the tibia and at 30° in the
lateral direction for the patella. 
Magnetic resonance spectroscopy. MRI and
1H-MRS were performed on a 3T scanner
(Signa LX; General Electric, Waukesha, WI).
Anatomical MR images were obtained in the
coronal plane using a 3D magnetization–pre-
pared rapid gradient echo (MPRAGE)
sequence developed in-house. The sequence
was acquired with a field of view of 24 cm,
32 slices with a 3-mm slice thickness, 256 ×
256 matrix size 600-msec inversion time, rep-
etition time (TR) of 8 msec, echo time (TE)
of 3 msec, a bandwidth of 32 kHz, and
1 excitation. These images were used to select
graphically the left and right hippocampus for
solvent suppressed 1H-MRS. Single-voxel
1H-MRS of the hippocampus was performed
using point-resolved spectroscopy (PRESS).
The 1H spectra (2 × 2 × 2c m 3) were acquired
with a repetition time of 2 sec, time to echo
of 35 msec, spectral width of 5,000 Hz, 2,048
time points, and 128 averages (4.3 min) and
an eight-step phase cycling scheme. Crusher
gradients of 32 mT/m amplitude (80% of the
full-scale system gradient amplitude) and a
duration of 4 msec (maximum crusher width)
were equally spaced around the 180° pulses
with 10-msec spacing. Spatial saturation
pulses were applied at the edge of the PRESS
voxel to minimize contamination of signal
from outside the prescribed voxel. Linear
shims were used to correct the B0 inhomo-
geneity across the investigated voxel. Spectral
analysis was performed using LC-Model
(Stephen Provencher Inc., Oakville, Ontario,
CN) embedded in the Spectroscopy Analysis
by GE package (SAGE) (GE Medical Systems,
Milwaukee, WI). After any upgrade to the
scanner we validated MRS results on phan-
toms. The output of LC-Model gave both the
metabolite ratios (expressed as relative concen-
tration taking into account the number of
protons in each compound) and their stan-
dard deviations. Peak assignments for the dif-
ferent metabolites were those routinely used
(Kreis et al. 1997). 
Data analysis. Analysis was performed on
the main metabolites detected by MRS, that
is, N-acetylaspartate (NAA), myoinositol
(mI), and choline (Cho), all expressed as a
ratio with creatine (Cr), which is generally
stable in the brain and normalizes the relative
intensities. When modeling the overall associ-
ation between bone lead biomarkers and
metabolite ratios, we included measurements
of metabolite ratios from the hippocampus on
both sides of the brain of each participant in
our analyses by using repeated measures, with
a compound symmetry covariance structure,
to account for the within subject correlation.
The MRS scans were performed an average of
6.0 (SD = 1.2) years after the KXRF measure-
ments; therefore, we report on additional
analyses after adjusting each subject’s patella
bone lead levels for the years between the
bone measurement and the MRS scan based
on a first-order exponential decay function
with a half-life of 8 years as determined previ-
ously among NAS participants (Kim et al.
1997). We did not adjust tibia concentrations
because the same previous study found that
they did not change over time periods similar
to those described here. Other data on sub-
jects were taken from their most recent regu-
lar NAS visit. Interquartile ranges (IQR) are
the values of a given distribution at the 25th
and 75th percentiles.
Results
Demographic and health characteristics of
NAS men selected for participation in this
study are shown in Table 1 according to
whether they participated and whether they
were in the low- or high-patella lead group.
When segregated by patella lead levels, there
was little difference between those men that
did and did not participate. None of the men
who participated had been diagnosed with
Alzheimer disease. In the complete NAS
cohort we have previously reported inverse
associations between bone lead and cognitive
function (Weisskopf et al. 2004b, 2007;
Wright et al. 2003), and in the small subset
that participated in this MRS study, the Mini-
Mental State Examination (Folstein et al.
1975) scores were higher among the low-lead
group (mean, 26.9; SD = 2.0) than among the
high-lead group (mean, 26.3; SD = 1.8). A
representative scan showing the voxel of inter-
est in the left hippocampus along with the
proton spectra is shown in Figure 1. Among
NAS men in the low-lead group the mean ±
SD mI/Cr, NAA/Cr, and Cho/Cr ratios were
0.89 ± 0.29, 1.26 ± 0.38, and 0.33 ± 0.09,
respectively. Among men in the high-lead
group, the mean ± SD ratios were 0.99 ± 0.25,
1.24 ± 0.31), and 0.41 ± 0.29).
In univariate analyses, both patella and tibia
bone lead were associated with a perturbation
of the mI/Cr ratio (Table 2). Among men in
the NAS with bone lead—from whom the 31
in this study were selected—the interquartile
range of patella and tibia lead concentration is
approximately 20 and 15 µg/g bone, respec-
tively (Weisskopf et al. 2007). A 20-µg/g bone
higher patella lead concentration and 15-µg/g
bone higher tibia lead concentration were asso-
ciated with an increase in mI/Cr ratio of 0.04
[95% conﬁdence interval (CI), 0.00–0.08; p =
0.03] and 0.04 (95% CI, 0.00–0.08; p = 0.06),
Weisskopf et al.
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Table 1. Characteristics by participation status and patella lead level.
Did not participate Participated
Patella lead level  Patella lead level
Characteristic Low (n = 90) High (n = 103) Low (n = 15) High (n = 16)
Mean age in years ± SD at MRSa 73.0 ± 6.2 78.0 ± 5.9 73.2 ± 4.7 80.7 ± 6.1
Mean years ± SD of education 15.3 ± 2.5 13.2 ± 2.6 16.3 ± 3.1 13.4 ± 2.6
Mean ± SD serum creatinine (mg/dL)  1.1 ± 0.5 1.1 ± 0.3 1.0 ± 0.2 1.2 ± 0.4
Mean ± SD systolic blood pressure (mmHg) 134 ± 16 134 ± 17 133 ± 15 135 ± 20
Diabetes, n (%) 7 (8) 5 (5) 0 1 (6)
Hypertension, n (%) 28 (31) 36 (35) 4 (27) 7 (44)
Taking hypertension medication, n (%) 9 (10) 15 (15) 1 (7) 6 (38)
Myocardial infarction, n (%) 0 6 (6) 0 1 (6)
Stroke, n (%) 0 3 (3) 0 1 (6)
Median (IQR) patella lead (µg/g bone) 10 (6–14) 48 (44–60) 9 (5–15) 63 (43–86)
Median (IQR) tibia lead (µg/g bone) 11 (7–17) 32 (24–41) 13 (9–17) 41 (38–59)
Hg, mercury. 
aAge on 1 January 2002 for those without MRS.respectively. Each of these effects represents
approximately 14% of the SD of the distribu-
tion of mI/Cr in the hippocampus among this
group. mI is an important component of the
phosphatidylinositol second messenger system,
and lithium treatment has been reported to
influence the brain levels of this metabolite
(Silverstone et al. 2005). None of the subjects
in our study used lithium.
When we adjusted for age in the models,
the effect sizes for both patella (0.05 per
20 µg/g) and tibia (0.05 per 15 µg/g) became
stronger than in the crude analyses, but the
precision was slightly reduced because of the
high correlation between age and bone lead.
None of the other metabolite ratios showed
significant associations with either patella or
tibia lead (Table 2). In analyses adjusted for
age and using patella lead levels adjusted to
account for decline in patella lead levels over
the time between bone lead measurement and
MRS, the results were also stronger than
those in the main analyses: the effect estimate
for a 20-µg/g bone patella lead increase was
almost double (0.09; 95% CI, 0.00–0.18; p =
0.04) that in the age-adjusted main analysis.
Figure 2 shows the individual mI/Cr ratios
adjusted to 75 years of age indicating this
association with patella lead. 
Renal insufﬁciency can affect lead burden
and possibly mI levels. Therefore, we also ran
analyses after excluding the two men with
serum creatinine > 1.5 mg/dL (one of whom
was the participant who reported both a pre-
vious myocardial infarction and stroke) and a
third man with diabetes, all three of whom
were in the high-lead group. In these analyses
the age-adjusted association between patella
lead adjusted to account for decline in lead
over time, and mI/Cr was even stronger than
in the main analyses (effect estimate per
20 µg/g bone: 0.11; 95% CI, 0.02–0.19; p =
0.02). In addition, we ran analyses adjusting
for hypertension (or use of hypertension med-
ication) because these were reported more fre-
quently in the high-lead group. In these
analyses the age-adjusted association between
patella lead adjusted to account for decline in
lead over time and mI/Cr was also stronger
than the main analyses (effect estimate per
20 µg/g bone: 0.13; 95% CI, 0.05–0.21; p =
0.002). Associations with other metabolite
ratios remained nonsigniﬁcant in all of these
additional analyses.
Discussion
In this analysis of elderly men with lifetime
exposures to lead similar to those of the gen-
eral U.S. population of similar age, we found
an association between an indicator of higher
cumulative lead exposure—measured by lead
concentration in bone—and increased mI/Cr
ratios in the hippocampal region. There were
no significant associations with any of the
other metabolite ratios. Results were more
pronounced when analyses were adjusted for
age, although less precise because of high cor-
relation between age and bone lead. However,
when adjusting for age in analyses of patella
lead adjusted for the time between the KXRF
and MRS, the association with mI/Cr was
both stronger and more precise. The magni-
tude of the increase in mI/Cr for an interquar-
tile range higher bone lead concentration was
about 14% of the SD of mI/Cr in this group. 
This study is, to our knowledge, the ﬁrst to
examine the association of cumulative exposure
to lead in a group of adults and metabolic
changes in brain as measured with MRS. It is
important to note that the exposure to lead in
our subjects is not occupational but rather from
the general environment and thus at levels that
a much larger population of elderly adults
worldwide would be expected to have. The few
previous studies of lead exposure and MRS
have focused on children. A study in China of
6 children with blood lead > 27 µg/dL and
6 children with blood lead < 10 µg/dL found
lower NAA/Cr ratios in both the frontal cortex
and hippocampus associated with the higher
lead exposure (Meng et al. 2005). mI levels
were not determined. A study in the United
States of 16 children with blood lead levels
between 23 and 65 µg/dL and 5 children with
blood lead < 10 µg/dL also found reduced
NAA/Cr, but no change in mI/Cr, in the
frontal cortex associated with the higher lead
exposure (Trope et al. 2001), which is similar
to their previous report of two cousins with dis-
parate lead exposure (Trope et al. 1998). In all
these studies the exposures were high. The aver-
age blood lead concentration of children
Cumulative lead exposure and MRS
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Table 2. Crude effect estimatesa for tibia and patella
lead on MRS metabolite ratios in the hippocampus. 
Effect
Metabolite estimate 95% CI p-Value
Patella lead
mI/Cr 0.04 0.00 to 0.08 0.03
NAA/Cr 0.00 –0.05 to 0.05 0.99
Cho/Cr –0.01 –0.04 to 0.02 0.42
Tibia lead
mI/Cr 0.04 0.00 to 0.08 0.06
NAA/Cr 0.00 –0.05 to 0.06 0.90
Cho/Cr –0.01 –0.04 to 0.03 0.66
aEffect estimates were per 20 and 15 µg/g increases in
patella and tibia lead concentration, respectively, which are
the interquartile ranges for those measures in the parent
Normative Aging Study population from which the subjects
in this study were selected. Because of missing metabolite
values the number of subjects in analyses of mI/Cr is 29.
Figure 1. Example MRI and magnetic resonance spectroscopy spectra from participants in the low (A) and
high (B) bone lead groups. The left panels show the region of interest outlined by a thick white box over-
lying the right hippocampal region on the MRIs. The right panels show the accompanying spectra with
peaks for mI, Cho, Cr, and NAA indicated. 
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12–19 years of age in the United States was
5.6 µg/dL in 2001–2002 (National Center for
Environmental Health 2005). Differences from
our current ﬁndings could be related to the age
or exposure level differences from these previ-
ous studies. The only study in adults examined
monozygotic twin brothers with markedly dif-
ferent lead levels—both blood and bone—
although they were dramatically elevated in
both twins as a result of occupational exposure
(Weisskopf et al. 2004a). The NAA/Cr ratio in
the hippocampus was found to be lower in the
twin with the higher lead levels. mI levels were
not determined. A principal difference in the
present study is that the exposures were chronic
and low level. Thus, the fact that changes in
mI/Cr but not in NAA/Cr were detected could
suggest that mI/Cr is a more sensitive indicator
than other metabolite ratios of chronic low-
level lead exposure in adults. 
In the cortex, NAA is located in neuronal
cell bodies, and a decrease in NAA is generally
accepted as an indicator of neuronal damage
and loss (Ross et al. 2006). In contrast, mI is
found primarily in glial cells. Inositol
polyphosphates are important neuronal signal-
ing molecules, but their concentrations in the
brain relative to mI itself are quite small and
they do not contribute to the MRS peak
assigned to mI, which is composed mostly of
mI alone and mI–monophosphate (Ross
1991). Although the pathological signiﬁcance
of elevated mI is not completely clear, it has
been proposed to reﬂect increased numbers of
glial cells (Brand et al. 1993; Ross et al. 2006).
Elevated mI and decreased NAA have been
widely reported in patients with Alzheimer
disease compared with normal controls in
neocortical, limbic cortical, and hippocampal
regions (Ross et al. 2006). Although other
dementias share the feature of a decrease in
NAA/Cr, the increase in mI/Cr is a relatively
distinctive aspect of Alzheimer disease and has
been suggested as indicative of gliosis
(Kantarci et al. 2004; Ross et al. 2006). It has
been proposed that the initial MRS changes in
the pathologic progression of Alzheimer dis-
ease is an increase in mI/Cr and that a
decrease in NAA/Cr develops later in the dis-
ease course, based on data from the posterior
cingulate gyrus (Kantarci et al. 2000). This is
supported by data indicating that glial prolif-
eration and plaque formation occur in preclin-
ical Alzheimer disease (Mackenzie et al. 1995;
Morris and Price 2001), whereas neuronal loss
may not occur at this stage (West et al. 2004).
The difference in mI/Cr reported between
Alzheimer disease patients and normal con-
trols (Kantarci et al. 2004; Ross et al. 2006) is
similar in magnitude to the change we found
associated with an interquartile range higher
patella bone lead concentration.
Little is known about the structural and
functional correlates of lead-related brain dys-
function in humans. Largely from in vitro and
animal work it is known that lead accumula-
tion in the brain after exposure is preferentially
in glia rather than in neurons (Lindahl et al.
1999; Tiffany-Castiglioni et al. 1989), and
chronic lead exposure in rats has been found
to induce astrogliosis in the hippocampus and
cerebellum (Selvin-Testa et al. 1994). The
astroglial response to lead exposure may in fact
be an initial attempt to protect neurons from
injury (Struzynska et al. 2005). Our results are
consistent with these animal studies. Although
lead most certainly adversely affects neurons as
well, it may be that, compared with effects on
glial cells, higher levels of lead exposure are
needed before those effects can be detected as
a reduced NAA/Cr ratio in humans with
MRS, and, therefore, the glial effects may be
an earlier MRS marker of effects of chronic
lead exposure.
A limitation to this study is the small sam-
ple size for study of the effects of relatively
low levels of lead exposure. Nonetheless, this
is the largest such study to date. Further study
of a larger cohort would provide better power
to detect possible other associations. Although
the participation rate was low, those that par-
ticipated and those that did not appeared sim-
ilar in many respects. An additional concern
is that participants in the high-lead group
were somewhat older than those in the low-
lead group. However, the mI/Cr ratio appears
to decrease with normal aging (Ross et al.
2006); thus our finding is in the opposite
direction of the possible age bias. Indeed, our
results were stronger when adjusted for age.
Another concern is that renal insufficiency
can affect lead burden and may inﬂuence mI
levels. However, our results were stronger
when the two men with serum creatinine
> 1.5 mg/dL and one man with diabetes were
excluded from analyses. Last, the region of
interest analyzed, while centering on the hip-
pocampus, includes some surrounding tissue.
Therefore, to the extent that the effects of
lead on metabolite ratios differ within and
immediately outside the hippocampus,
observed associations would be weakened. 
In summary, we find an association
between increased cumulative lead exposure
and increased mI/Cr ratios in the hippocam-
pus among a group with general population
levels of lead exposure. We did not see signiﬁ-
cant associations between lead and any of the
other metabolite ratios. These data suggest
that in humans, as has been seen in animal
studies, glial effects may also be the first or
most sensitive indicators of adverse effects of
cumulative lead exposure in adults, and these
changes are similar to what is seen in early
stages of Alzheimer disease.
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